APO Research
Talk to an analyst

APO RESEARCH · REPORT

LGR5 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global LGR5 Antibody Market Outlook and Growth Opportunities 2026

19 December 2025197 pages

Choose your research edition.

Industry ResearchLGR5 Antibody Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal LGR5 Antibody Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal LGR5 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal LGR5 Antibody Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal LGR5 Antibody Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global LGR5 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for LGR5 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for LGR5 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for LGR5 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the LGR5 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the LGR5 Antibody market include Thermo Fisher Scientific, Merck, United States Biological, Proteintech, OriGene, NSJ Bioreagents, Miltenyi Biotec, HUABIO and GeneTex, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global LGR5 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of LGR5 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents LGR5 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global LGR5 Antibody market.

LGR5 Antibody Segment by Company

Thermo Fisher Scientific

Merck

United States Biological

Proteintech

OriGene

NSJ Bioreagents

Miltenyi Biotec

HUABIO

GeneTex

Boster Biological Technology

Bioss

Bio-Rad

BioLegend

Abcam

LGR5 Antibody Segment by Type

Polyclonal

Monoclonal

LGR5 Antibody Segment by Application

Western Blot

Immunoprecipitation

Immunofluorescence

Immunohistochemistry

Others

LGR5 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global LGR5 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the LGR5 Antibody key companies, revenue, market share, and recent developments.

3. To split the LGR5 Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions LGR5 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify LGR5 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze LGR5 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global LGR5 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of LGR5 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of LGR5 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global LGR5 Antibody industry.

Chapter 3: Detailed analysis of LGR5 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of LGR5 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of LGR5 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. LGR5 Antibody Industry Trends Table 2. LGR5 Antibody Industry Drivers Table 3. LGR5 Antibody Industry Opportunities and Challenges Table 4. LGR5 Antibody Industry Restraints Table 5. Global LGR5 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global LGR5 Antibody Revenue Share by Company (2021-2026) Table 7. Global LGR5 Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global LGR5 Antibody Key Company Manufacturing Base & Headquarters Table 9. Global LGR5 Antibody Company, Product Type & Application Table 10. Global LGR5 Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global LGR5 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global LGR5 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global LGR5 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global LGR5 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global LGR5 Antibody Sales Value Share by Type (2021-2026) Table 20. Global LGR5 Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Western Blot Table 22. Significant Companies of Immunoprecipitation Table 23. Significant Companies of Immunofluorescence Table 24. Significant Companies of Immunohistochemistry Table 25. Significant Companies of Others Table 26. Global LGR5 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global LGR5 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global LGR5 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global LGR5 Antibody Sales Value Share by Application (2021-2026) Table 30. Global LGR5 Antibody Sales Value Share by Application (2027-2032) Table 31. Global LGR5 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global LGR5 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global LGR5 Antibody Sales Value Share by Region (2021-2026) Table 34. Global LGR5 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global LGR5 Antibody Sales Value Share by Region (2027-2032) Table 36. Global LGR5 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global LGR5 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global LGR5 Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global LGR5 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global LGR5 Antibody Sales Value Market Share by Country (2027-2032) Table 41. Thermo Fisher Scientific Company Information Table 42. Thermo Fisher Scientific Business Overview Table 43. Thermo Fisher Scientific LGR5 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Thermo Fisher Scientific LGR5 Antibody Product Portfolio Table 45. Thermo Fisher Scientific Recent Development Table 46. Merck Company Information Table 47. Merck Business Overview Table 48. Merck LGR5 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Merck LGR5 Antibody Product Portfolio Table 50. Merck Recent Development Table 51. United States Biological Company Information Table 52. United States Biological Business Overview Table 53. United States Biological LGR5 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. United States Biological LGR5 Antibody Product Portfolio Table 55. United States Biological Recent Development Table 56. Proteintech Company Information Table 57. Proteintech Business Overview Table 58. Proteintech LGR5 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Proteintech LGR5 Antibody Product Portfolio Table 60. Proteintech Recent Development Table 61. OriGene Company Information Table 62. OriGene Business Overview Table 63. OriGene LGR5 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. OriGene LGR5 Antibody Product Portfolio Table 65. OriGene Recent Development Table 66. NSJ Bioreagents Company Information Table 67. NSJ Bioreagents Business Overview Table 68. NSJ Bioreagents LGR5 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. NSJ Bioreagents LGR5 Antibody Product Portfolio Table 70. NSJ Bioreagents Recent Development Table 71. Miltenyi Biotec Company Information Table 72. Miltenyi Biotec Business Overview Table 73. Miltenyi Biotec LGR5 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Miltenyi Biotec LGR5 Antibody Product Portfolio Table 75. Miltenyi Biotec Recent Development Table 76. HUABIO Company Information Table 77. HUABIO Business Overview Table 78. HUABIO LGR5 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. HUABIO LGR5 Antibody Product Portfolio Table 80. HUABIO Recent Development Table 81. GeneTex Company Information Table 82. GeneTex Business Overview Table 83. GeneTex LGR5 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. GeneTex LGR5 Antibody Product Portfolio Table 85. GeneTex Recent Development Table 86. Boster Biological Technology Company Information Table 87. Boster Biological Technology Business Overview Table 88. Boster Biological Technology LGR5 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Boster Biological Technology LGR5 Antibody Product Portfolio Table 90. Boster Biological Technology Recent Development Table 91. Bioss Company Information Table 92. Bioss Business Overview Table 93. Bioss LGR5 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Bioss LGR5 Antibody Product Portfolio Table 95. Bioss Recent Development Table 96. Bio-Rad Company Information Table 97. Bio-Rad Business Overview Table 98. Bio-Rad LGR5 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Bio-Rad LGR5 Antibody Product Portfolio Table 100. Bio-Rad Recent Development Table 101. BioLegend Company Information Table 102. BioLegend Business Overview Table 103. BioLegend LGR5 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. BioLegend LGR5 Antibody Product Portfolio Table 105. BioLegend Recent Development Table 106. Abcam Company Information Table 107. Abcam Business Overview Table 108. Abcam LGR5 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Abcam LGR5 Antibody Product Portfolio Table 110. Abcam Recent Development Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. LGR5 Antibody Product Image Figure 2. Global LGR5 Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global LGR5 Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global LGR5 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global LGR5 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global LGR5 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global LGR5 Antibody Sales Value Share by Type (2021-2032) Figure 12. Western Blot Image Figure 13. Immunoprecipitation Image Figure 14. Immunofluorescence Image Figure 15. Immunohistochemistry Image Figure 16. Others Image Figure 17. Global LGR5 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global LGR5 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global LGR5 Antibody Sales Value Share by Application (2021-2032) Figure 20. Global LGR5 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global LGR5 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America LGR5 Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America LGR5 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe LGR5 Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe LGR5 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific LGR5 Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific LGR5 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America LGR5 Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America LGR5 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa LGR5 Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa LGR5 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt LGR5 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt LGR5 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt LGR5 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Western Blot
  • Immunoprecipitation
  • Immunofluorescence
  • Immunohistochemistry
  • Others
Companies covered
  • Thermo Fisher Scientific
  • Merck
  • United States Biological
  • Proteintech
  • OriGene
  • NSJ Bioreagents
  • Miltenyi Biotec
  • HUABIO
  • GeneTex
  • Boster Biological Technology
  • Bioss
  • Bio-Rad
  • BioLegend
  • Abcam

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global LGR5 Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global LGR5 Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 LGR5 Antibody Market Dynamics
  1. 2.1 LGR5 Antibody Industry Trends
  2. 2.2 LGR5 Antibody Industry Drivers
  3. 2.3 LGR5 Antibody Industry Opportunities and Challenges
  4. 2.4 LGR5 Antibody Industry Restraints
3 LGR5 Antibody Market by Company
  1. 3.1 Global LGR5 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global LGR5 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global LGR5 Antibody Company Ranking (2024-2026)
  4. 3.4 Global LGR5 Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global LGR5 Antibody Company Product Type and Application
  6. 3.6 Global LGR5 Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global LGR5 Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 LGR5 Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 LGR5 Antibody Market by Type
  1. 4.1 LGR5 Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global LGR5 Antibody Sales Value by Type
  5. 4.2.1 Global LGR5 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global LGR5 Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global LGR5 Antibody Sales Value Share by Type (2021-2032)
5 LGR5 Antibody Market by Application
  1. 5.1 LGR5 Antibody Application Introduction
  2. 5.1.1 Western Blot
  3. 5.1.2 Immunoprecipitation
  4. 5.1.3 Immunofluorescence
  5. 5.1.4 Immunohistochemistry
  6. 5.1.5 Others
  7. 5.2 Global LGR5 Antibody Sales Value by Application
  8. 5.2.1 Global LGR5 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global LGR5 Antibody Sales Value by Application (2021-2032)
  10. 5.2.3 Global LGR5 Antibody Sales Value Share by Application (2021-2032)
6 LGR5 Antibody Regional Value Analysis
  1. 6.1 Global LGR5 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global LGR5 Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global LGR5 Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global LGR5 Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America LGR5 Antibody Sales Value (2021-2032)
  7. 6.3.2 North America LGR5 Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe LGR5 Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe LGR5 Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific LGR5 Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific LGR5 Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America LGR5 Antibody Sales Value (2021-2032)
  16. 6.6.2 South America LGR5 Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa LGR5 Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa LGR5 Antibody Sales Value Share by Country, 2025 VS 2032
7 LGR5 Antibody Country-level Value Analysis
  1. 7.1 Global LGR5 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global LGR5 Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global LGR5 Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global LGR5 Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA LGR5 Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada LGR5 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico LGR5 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany LGR5 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France LGR5 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. LGR5 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy LGR5 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain LGR5 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia LGR5 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands LGR5 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries LGR5 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China LGR5 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan LGR5 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea LGR5 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India LGR5 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia LGR5 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia LGR5 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil LGR5 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina LGR5 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile LGR5 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia LGR5 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru LGR5 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia LGR5 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel LGR5 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE LGR5 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey LGR5 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran LGR5 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt LGR5 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt LGR5 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt LGR5 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific LGR5 Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific LGR5 Antibody Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck LGR5 Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck LGR5 Antibody Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 United States Biological
  14. 8.3.1 United States Biological Company Information
  15. 8.3.2 United States Biological Business Overview
  16. 8.3.3 United States Biological LGR5 Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 United States Biological LGR5 Antibody Product Portfolio
  18. 8.3.5 United States Biological Recent Developments
  19. 8.4 Proteintech
  20. 8.4.1 Proteintech Company Information
  21. 8.4.2 Proteintech Business Overview
  22. 8.4.3 Proteintech LGR5 Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Proteintech LGR5 Antibody Product Portfolio
  24. 8.4.5 Proteintech Recent Developments
  25. 8.5 OriGene
  26. 8.5.1 OriGene Company Information
  27. 8.5.2 OriGene Business Overview
  28. 8.5.3 OriGene LGR5 Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 OriGene LGR5 Antibody Product Portfolio
  30. 8.5.5 OriGene Recent Developments
  31. 8.6 NSJ Bioreagents
  32. 8.6.1 NSJ Bioreagents Company Information
  33. 8.6.2 NSJ Bioreagents Business Overview
  34. 8.6.3 NSJ Bioreagents LGR5 Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 NSJ Bioreagents LGR5 Antibody Product Portfolio
  36. 8.6.5 NSJ Bioreagents Recent Developments
  37. 8.7 Miltenyi Biotec
  38. 8.7.1 Miltenyi Biotec Company Information
  39. 8.7.2 Miltenyi Biotec Business Overview
  40. 8.7.3 Miltenyi Biotec LGR5 Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Miltenyi Biotec LGR5 Antibody Product Portfolio
  42. 8.7.5 Miltenyi Biotec Recent Developments
  43. 8.8 HUABIO
  44. 8.8.1 HUABIO Company Information
  45. 8.8.2 HUABIO Business Overview
  46. 8.8.3 HUABIO LGR5 Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 HUABIO LGR5 Antibody Product Portfolio
  48. 8.8.5 HUABIO Recent Developments
  49. 8.9 GeneTex
  50. 8.9.1 GeneTex Company Information
  51. 8.9.2 GeneTex Business Overview
  52. 8.9.3 GeneTex LGR5 Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GeneTex LGR5 Antibody Product Portfolio
  54. 8.9.5 GeneTex Recent Developments
  55. 8.10 Boster Biological Technology
  56. 8.10.1 Boster Biological Technology Company Information
  57. 8.10.2 Boster Biological Technology Business Overview
  58. 8.10.3 Boster Biological Technology LGR5 Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boster Biological Technology LGR5 Antibody Product Portfolio
  60. 8.10.5 Boster Biological Technology Recent Developments
  61. 8.11 Bioss
  62. 8.11.1 Bioss Company Information
  63. 8.11.2 Bioss Business Overview
  64. 8.11.3 Bioss LGR5 Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bioss LGR5 Antibody Product Portfolio
  66. 8.11.5 Bioss Recent Developments
  67. 8.12 Bio-Rad
  68. 8.12.1 Bio-Rad Company Information
  69. 8.12.2 Bio-Rad Business Overview
  70. 8.12.3 Bio-Rad LGR5 Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bio-Rad LGR5 Antibody Product Portfolio
  72. 8.12.5 Bio-Rad Recent Developments
  73. 8.13 BioLegend
  74. 8.13.1 BioLegend Company Information
  75. 8.13.2 BioLegend Business Overview
  76. 8.13.3 BioLegend LGR5 Antibody Revenue and Gross Margin (2021-2026)
  77. 8.13.4 BioLegend LGR5 Antibody Product Portfolio
  78. 8.13.5 BioLegend Recent Developments
  79. 8.14 Abcam
  80. 8.14.1 Abcam Company Information
  81. 8.14.2 Abcam Business Overview
  82. 8.14.3 Abcam LGR5 Antibody Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Abcam LGR5 Antibody Product Portfolio
  84. 8.14.5 Abcam Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst